RÉSUMÉ
Human metapneumovirus (hMPV) is a respiratory pathogen that can cause lower respiratory tract infections and pneumonia in immunocompetent adults. Pneumonia caused by hMPV is reportedly more likely to cause bronchial wall thickening and ground-glass opacity (GGO). A 44-year-old woman with no significant medical history developed fever, cough, and nausea. Computed tomography of the chest showed scattered GGOs in the right upper lobe and infiltrating shadows with air bronchograms in the left lingual and bilateral lower lobes. The patient was admitted to our hospital for further evaluation. Atypical pneumonia was suspected and lascufloxacin (LSFX) was started. Multiplex polymerase chain reaction (PCR) detected hMPV on hospital day 2 using the FilmArray Respiratory Panel 2.1. Pneumonia due to hMPV was suspected and LSFX was discontinued. The patient subsequently showed spontaneous improvement and was discharged on hospital day 6 after admission. After discharge, pneumonia continued to improve. Early detection of respiratory pathogens using multiplex PCR can help determine the appropriate treatment strategy. As hMPV can also cause lobar pneumonia, we should consider pneumonia due to hMPV in the differential diagnosis of lobar pneumonia.
Sujet(s)
Metapneumovirus , Infections à Paramyxoviridae , Pneumopathie virale , Tomodensitométrie , Humains , Metapneumovirus/isolement et purification , Metapneumovirus/génétique , Adulte , Femelle , Infections à Paramyxoviridae/diagnostic , Infections à Paramyxoviridae/virologie , Infections à Paramyxoviridae/traitement médicamenteux , Pneumopathie virale/diagnostic , Pneumopathie virale/virologie , Pneumopathie virale/traitement médicamenteux , Réaction de polymérisation en chaine multiplexRÉSUMÉ
Human metapneumovirus (HMPV) is an important cause of acute respiratory tract infection and causes significant morbidity and mortality. There is no specific antiviral drug to treat HMPV or vaccine to prevent HMPV. This study determined if probenecid, a host-targeting antiviral drug, had prophylactic (pre-virus) or therapeutic (post-virus) efficacy to inhibit HMPV replication in LLC-MK2 cells in vitro and in the lungs of BALB/c mice. This study showed that ≥0.5 µM probenecid significantly inhibited HMPV replication in vitro, and 2-200 mg/kg probenecid prophylaxis or treatment reduced HMPV replication in BALB/c mice.
Sujet(s)
Antiviraux , Metapneumovirus , Souris de lignée BALB C , Infections à Paramyxoviridae , Probénécide , Réplication virale , Animaux , Metapneumovirus/effets des médicaments et des substances chimiques , Metapneumovirus/physiologie , Réplication virale/effets des médicaments et des substances chimiques , Souris , Probénécide/pharmacologie , Infections à Paramyxoviridae/traitement médicamenteux , Infections à Paramyxoviridae/virologie , Antiviraux/pharmacologie , Lignée cellulaire , Poumon/virologie , Humains , Infections de l'appareil respiratoire/virologie , Infections de l'appareil respiratoire/traitement médicamenteux , FemelleRÉSUMÉ
Objective: To investigate the genotype and epidemiological characteristics of human metapneumovirus (HMPV) among hospitalized cases with acute respiratory infections (ARI) in children in Changchun City, Jilin Province, China. Methods: From June 2019 to June 2023, throat swabs of ARI inpatients in Changchun Children's Hospital were collected, and their epidemiological and clinical information were also collected. Quantitative reverse transcription-PCR was used to identify HMPV-positive cases, followed by the amplification of the G gene and genetic analysis in the HMPV-positive cases. Results: A total of 3 311 children hospitalized with ARI were included in this study. Their age ranged from 0 to 17 years old, and the M (Q1, Q3) of age was 2 (1, 3) years. About 1 811 (54.70%) cases were males. A total of 167 HMPV-positive cases were detected with a positive rate of 5.04%, of which 92.81% (155/167) were children under 5 years old. The positive rate of HMPV in 2019 was 6.37% (30/471), which dropped to the lowest in 2020 (2.31%, 10/432). The HMPV-positive rate was then rebounded in 2021 (4.70%, 60/1 277) and 2022 (4.56%, 21/461), which increased to 6.87% (46/670) in 2023. The difference in HMPV-positive rate among each year was statistically significant (P<0.05). The prevalence peak of HMPV varied in different years, showing either a unimodal or bimodal distribution in one year. A total of 79 HMPV G gene sequences were obtained, of which subtype A and subtype B accounted for 48.10% and 51.90%, respectively. All of the subtype A sequences were clarified as A2c duplicated variants, and subtype B was mainly B2 genotype. Besides, subtypes A and B were prevalent alone or co-circulated in different years, and there was a subtype replacement pattern in HMPV. Conclusion: The positive rate of HMPV in hospitalized ARI cases in children is significantly different from 2019 to 2023 in Changchun City. Notably, there are certain switch patterns of HMPV subtypes A and B in different years.
Sujet(s)
Génotype , Metapneumovirus , Infections à Paramyxoviridae , Infections de l'appareil respiratoire , Humains , Metapneumovirus/génétique , Metapneumovirus/classification , Infections de l'appareil respiratoire/épidémiologie , Infections de l'appareil respiratoire/virologie , Enfant , Enfant d'âge préscolaire , Nourrisson , Chine/épidémiologie , Mâle , Adolescent , Femelle , Infections à Paramyxoviridae/épidémiologie , Infections à Paramyxoviridae/virologie , Maladie aigüe , Hospitalisation , Nouveau-né , PhylogenèseRÉSUMÉ
The prefusion conformation of human metapneumovirus fusion protein (hMPV Pre-F) is critical for eliciting the most potent neutralizing antibodies and is the preferred immunogen for an efficacious vaccine against hMPV respiratory infections. Here we show that an additional cleavage event in the F protein allows closure and correct folding of the trimer. We therefore engineered the F protein to undergo double cleavage, which enabled screening for Pre-F stabilizing substitutions at the natively folded protomer interfaces. To identify these substitutions, we developed an AI convolutional classifier that successfully predicts complex polar interactions often overlooked by physics-based methods and visual inspection. The combination of additional processing, stabilization of interface regions and stabilization of the membrane-proximal stem, resulted in a Pre-F protein vaccine candidate without the need for a heterologous trimerization domain that exhibited high expression yields and thermostability. Cryo-EM analysis shows the complete ectodomain structure, including the stem, and a specific interaction of the newly identified cleaved C-terminus with the adjacent protomer. Importantly, the protein induces high and cross-neutralizing antibody responses resulting in near complete protection against hMPV challenge in cotton rats, making the highly stable, double-cleaved hMPV Pre-F trimer an attractive vaccine candidate.
Sujet(s)
Anticorps neutralisants , Anticorps antiviraux , Metapneumovirus , Protéines de fusion virale , Vaccins antiviraux , Metapneumovirus/immunologie , Metapneumovirus/génétique , Animaux , Anticorps neutralisants/immunologie , Humains , Anticorps antiviraux/immunologie , Protéines de fusion virale/immunologie , Protéines de fusion virale/composition chimique , Protéines de fusion virale/génétique , Vaccins antiviraux/immunologie , Infections à Paramyxoviridae/prévention et contrôle , Infections à Paramyxoviridae/immunologie , Cryomicroscopie électronique , Ingénierie des protéines/méthodes , Sigmodontinae , Femelle , Multimérisation de protéines , Modèles moléculairesRÉSUMÉ
Airborne animal viral pathogens can rapidly spread and become a global threat, resulting in substantial socioeconomic and health consequences. To prevent and control potential epidemic outbreaks, accurate, fast, and affordable point-of-care (POC) tests are essential. As a proof-of-concept, we have developed a molecular system based on the loop-mediated isothermal amplification (LAMP) technique for avian metapneumovirus (aMPV) detection, an airborne communicable agent mainly infecting turkeys and chickens. For this purpose, a colorimetric system was obtained by coupling the LAMP technique with specific DNA-functionalized AuNPs (gold nanoparticles). The system was validated using 50 different samples (pharyngeal swabs and tracheal tissue) collected from aMPV-infected and non-infected chickens and turkeys. Viral detection can be achieved in about 60 min with the naked eye, with 100% specificity and 87.88% sensitivity for aMPV. In summary, this novel molecular detection system allows suitable virus testing in the field, with accuracy and limit of detection (LOD) values highly close to qRT-PCR-based diagnosis. Furthermore, this system can be easily scalable to a platform for the detection of other viruses, addressing the current gap in the availability of POC tests for viral detection in poultry farming. KEY POINTS: â¢aMPV diagnosis using RT-LAMP is achieved with high sensitivity and specificity. â¢Fifty field samples have been visualized using DNA-nanoprobe validation. â¢The developed system is a reliable, fast, and cost-effective option for POCT.
Sujet(s)
Poulets , Or , Metapneumovirus , Techniques de diagnostic moléculaire , Techniques d'amplification d'acides nucléiques , Infections à Paramyxoviridae , Maladies de la volaille , Sensibilité et spécificité , Metapneumovirus/génétique , Metapneumovirus/isolement et purification , Animaux , Techniques d'amplification d'acides nucléiques/méthodes , Techniques d'amplification d'acides nucléiques/économie , Poulets/virologie , Techniques de diagnostic moléculaire/méthodes , Techniques de diagnostic moléculaire/économie , Infections à Paramyxoviridae/diagnostic , Infections à Paramyxoviridae/médecine vétérinaire , Infections à Paramyxoviridae/virologie , Maladies de la volaille/virologie , Maladies de la volaille/diagnostic , Or/composition chimique , Dindons , Nanoparticules métalliques/composition chimique , Limite de détection , Colorimétrie/méthodes , ADN viral/génétiqueRÉSUMÉ
BACKGROUND: Respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and influenza virus are responsible for acute respiratory tract infections (ARTIs) in adults. We assessed the clinical burden of RSV, hMPV and influenza virus infection among Japanese adults hospitalized with ARTIs. METHODS: The Hospitalized Acute Respiratory Tract Infection (HARTI) study was a multinational, prospective cohort study in adults with ARTIs across the 2017-2019 epidemic seasons. Enrolment in Japan began in Sept 2018 and ran until Oct 2019. The clinical diagnosis of ARTI and the decision to hospitalize the patient were made according to local standard of care practices. Viral testing was performed by reverse transcription polymerase chain reaction. RESULTS: Of the 173 adults hospitalized with ARTI during this period at the Japan sites, 7 (4.0%), 9 (5.2%), and 11 (6.4%) were positive for influenza virus, RSV, and hMPV, respectively. RSV season was observed from Oct 2018 to Jan 2019, followed by influenza from Dec 2018 to Apr 2019. hMPV was detected across both the RSV and influenza seasons. Two patients with RSV and 1 patient with hMPV required ICU admission whereas none with influenza. Use of antibiotics, bronchodilators and inhaled corticosteroids was high amongst patients with RSV and hMPV at 1, 2, and 3 months' post-discharge compared with patients with influenza, with few exceptions. CONCLUSION: These findings highlight the need for a high degree of clinical suspicion for RSV and hMPV infection in adults hospitalized with ARTIs.
Sujet(s)
Hospitalisation , Grippe humaine , Infections à Paramyxoviridae , Infections à virus respiratoire syncytial , Infections de l'appareil respiratoire , Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Maladie aigüe , Études de cohortes , Coûts indirects de la maladie , Peuples d'Asie de l'Est , Hospitalisation/statistiques et données numériques , Grippe humaine/épidémiologie , Japon/épidémiologie , Infections à Paramyxoviridae/épidémiologie , Études prospectives , Infections à virus respiratoire syncytial/épidémiologie , Infections de l'appareil respiratoire/épidémiologie , Infections de l'appareil respiratoire/virologieRÉSUMÉ
BACKGROUND: Human parainfluenza viruses (HPIVs) commonly cause childhood respiratory illness requiring hospitalization in Taiwan. This study aimed to investigate clinical severity and identify risk factors predisposing to severe disease in hospitalized children with HPIV infection. METHODS: We included hospitalized patients with lab-confirmed HPIV infection from 2007 to 2018 and collected their demographic and clinical characteristics. Patients with ventilator support, intravenous inotropic agents, and extracorporeal membrane oxygenation were defined as severe cases. RESULTS: There were 554 children hospitalized for HPIV infection. The median age was 1.2 years; 518 patients had non-severe HPIV infection, whereas 36 patients (6.5%) had severe HPIV infection. 266 (48%) patients had underlying diseases, and 190 patients (34.3%) had bacterial co-detection. Children with severe HPIV infection were more likely to have bacterial co-detection than those without (52.8% vs 33.0%, p = 0.02). Patients with lung patch or consolidation had more invasive bacterial co-infection or co-detection than those without patch or consolidation (43% vs 33%, p = 0.06). Patients with neurological disease (adjusted OR 4.77, 95% CI 1.94-11.68), lung consolidation/patch (adjusted OR 6.64, 95% CI 2.80-15.75), and effusion (adjusted OR 11.59, 95% CI 1.52-88.36) had significantly higher risk to have severe HPIV infection. CONCLUSION: Neurological disease and lung consolidation/patch or effusion were the most significant predictors of severe HPIV infection.
Sujet(s)
Co-infection , Hospitalisation , Infections à Paramyxoviridae , Humains , Mâle , Femelle , Facteurs de risque , Nourrisson , Enfant d'âge préscolaire , Taïwan/épidémiologie , Enfant , Infections à Paramyxoviridae/épidémiologie , Infections à Paramyxoviridae/complications , Co-infection/épidémiologie , Co-infection/virologie , Co-infection/microbiologie , Indice de gravité de la maladie , Enfant hospitalisé/statistiques et données numériques , Oxygénation extracorporelle sur oxygénateur à membrane , Adolescent , Études rétrospectives , Infections de l'appareil respiratoire/virologie , Infections de l'appareil respiratoire/épidémiologie , Infections bactériennes/épidémiologieRÉSUMÉ
Introduction: Community-acquired pneumonia (CAP) is a global health concern, with 25% of cases attributed to Streptococcus pneumoniae (Spn). Viral infections like influenza A virus (IAV), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV) increase the risk of Spn, leading to severe complications due to compromised host immunity. Methods: We evaluated the efficacy of an anti-PhtD monoclonal antibody (mAb) cocktail therapy (PhtD3 + 7) in improving survival rates in three viral/bacterial coinfection models: IAV/Spn, hMPV/Spn, and RSV/Spn. Results: The PhtD3 + 7 mAb cocktail outperformed antiviral mAbs, resulting in prolonged survival. In the IAV/Spn model, it reduced bacterial titers in blood and lungs by 2-4 logs. In the hMPV/Spn model, PhtD3 + 7 provided greater protection than the hMPV-neutralizing mAb MPV467, significantly reducing bacterial titers. In the RSV/Spn model, PhtD3 + 7 offered slightly better protection than the antiviral mAb D25, uniquely decreasing bacterial titers in blood and lungs. Discussion: Given the threat of antibiotic resistance, our findings highlight the potential of anti-PhtD mAb therapy as an effective option for treating viral and secondary pneumococcal coinfections.
Sujet(s)
Anticorps monoclonaux , Co-infection , Streptococcus pneumoniae , Surinfection , Animaux , Humains , Anticorps monoclonaux/usage thérapeutique , Anticorps monoclonaux/pharmacologie , Anticorps monoclonaux/immunologie , Streptococcus pneumoniae/immunologie , Souris , Surinfection/immunologie , Surinfection/microbiologie , Co-infection/immunologie , Infections à virus respiratoire syncytial/immunologie , Infections à virus respiratoire syncytial/traitement médicamenteux , Metapneumovirus/immunologie , Virus de la grippe A/immunologie , Modèles animaux de maladie humaine , Infections à pneumocoques/immunologie , Infections à pneumocoques/prévention et contrôle , Infections à pneumocoques/traitement médicamenteux , Femelle , Souris de lignée BALB C , Infections à Paramyxoviridae/immunologie , Infections à Paramyxoviridae/traitement médicamenteux , Anticorps antiviraux/immunologieRÉSUMÉ
The genus Jeilongvirus comprises non-segmented negative-stranded RNA viruses that are classified within the Paramyxoviridae family by phylogeny. Jeilongviruses are found in various reservoirs, including rodents and bats. Rodents are typical viral reservoirs with diverse spectra and zoonotic potential. Little is currently known about jeilongviruses in rodents from central China. The study utilized high-throughput and Sanger sequencing to obtain jeilongvirus genomes, including those of two novel strains (HBJZ120/CHN/2021 (17,468 nt) and HBJZ157/CHN/2021 (19,143 nt)) and three known viruses (HBXN18/CHN/2021 (19,212 nt), HBJZ10/CHN/2021 (19,700 nt), HBJM106/CHN/2021 (18,871 nt)), which were characterized by genome structure, identity matrix, and phylogenetic analysis. Jeilongviruses were classified into three subclades based on their topology, phylogeny, and hosts. Based on the amino acid sequence identities and phylogenetic analysis of the L protein, HBJZ120/CHN/2021 and HBJZ157/CHN/2021 were found to be strains rather than novel species. Additionally, according to specific polymerase chain reaction screening, the positive percentage of Beilong virus in Hubei was 6.38%, suggesting that Beilong virus, belonging to the Jeilongvirus genus, is likely to be widespread in wild rodents. The identification of novel strains further elucidated the genomic diversity of jeilongviruses. Additionally, the prevalence of jeilongviruses in Hubei, China, was profiled, establishing a foundation for the surveillance and early warning of emerging paramyxoviruses.
Sujet(s)
Génome viral , Phylogenèse , Rodentia , Animaux , Chine , Rodentia/virologie , Animaux sauvages/virologie , Paramyxovirinae/génétique , Paramyxovirinae/classification , Paramyxovirinae/isolement et purification , ARN viral/génétique , Infections à Paramyxoviridae/médecine vétérinaire , Infections à Paramyxoviridae/virologie , Infections à Paramyxoviridae/épidémiologie , Séquençage nucléotidique à haut débit , Réservoirs de maladies/virologie , Analyse de séquence d'ADNRÉSUMÉ
This study evaluated the epidemiological and clinical characteristics of human metapneumovirus (hMPV) infection among hospitalized patients with acute respiratory infections during 2015-2021 and assessed the impact of the coronavirus disease 2019 pandemic on hMPV infection. A single-center, retrospective cohort study was performed, including pediatric and adult patients with laboratory-confirmed hMPV. Of a total of 990 patients, 253 (25.6%), 105 (10.6%), 121 (12.2%), and 511 (51.6%) belonged to age groups 0-2, 3-17, 18-59, and ≥60 years, respectively. The highest percentage (23.0%) of patients were hospitalized during 2019 and the lowest (4.7%) during 2020. Patients < 18 years experienced high rates of comorbidities (immunodeficiencies: 14.4% and malignancies: 29.9%). Here, 37/39 (94.9%) of all bronchiolitis cases were diagnosed in patients < 2 years, whereas more patients in older age groups were diagnosed with pneumonia. A greater proportion of hMPV patients diagnosed with viral coinfection (mostly respiratory syncytial virus and adenovirus) were <18 years. The highest percentages of intensive care unit admissions were recorded among patients < 18 years. Our findings demonstrate that hMPV is an important cause of morbidity in young children and a possibly underestimated cause of morbidity among older adults.
Sujet(s)
COVID-19 , Co-infection , Hospitalisation , Metapneumovirus , Infections à Paramyxoviridae , Humains , Études rétrospectives , Metapneumovirus/isolement et purification , Infections à Paramyxoviridae/épidémiologie , Infections à Paramyxoviridae/virologie , Israël/épidémiologie , Adulte d'âge moyen , Enfant , Mâle , Adulte , Femelle , Nourrisson , Adolescent , Enfant d'âge préscolaire , Hospitalisation/statistiques et données numériques , Jeune adulte , COVID-19/épidémiologie , COVID-19/virologie , Sujet âgé , Co-infection/épidémiologie , Co-infection/virologie , Nouveau-né , Infections de l'appareil respiratoire/épidémiologie , Infections de l'appareil respiratoire/virologie , Comorbidité , Sujet âgé de 80 ans ou plus , SARS-CoV-2RÉSUMÉ
OBJECTIVES: Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) are common respiratory illnesses in children. The safety and immunogenicity of an investigational mRNA-based vaccine, mRNA-1653, encoding membrane-anchored fusion proteins of hMPV and PIV3, was evaluated in hMPV/PIV3-seropositive children. METHODS: In this phase 1b randomized, observer-blind, placebo-controlled, dose-ranging study, hMPV/PIV3-seropositive children were enrolled sequentially into 2 dose levels of mRNA-1653 administered 2 months apart; children aged 12 to 36 months were randomized (1:1) to receive 10-µg of mRNA-1653 or placebo and children aged 12 to 59 months were randomized (3:1) to receive 30-µg of mRNA-1653 or placebo. RESULTS: Overall, 27 participants aged 18 to 55 months were randomized; 15 participants received 10-µg of mRNA-1653 (n = 8) or placebo (n = 7), whereas 12 participants received 30-µg of mRNA-1653 (n = 9) or placebo (n = 3). mRNA-1653 was well-tolerated at both dose levels. The only reported solicited local adverse reaction was tenderness at injection site; solicited systemic adverse reactions included grade 1 or 2 chills, irritability, loss of appetite, and sleepiness. A single 10-µg or 30-µg mRNA-1653 injection increased hMPV and PIV3 neutralizing antibody titers (geometric mean fold-rise ratio over baseline: hMPV-A = 2.9-6.1; hMPV-B = 6.2-13.2; PIV3 = 2.8-3.0) and preF and postF binding antibody concentrations (geometric mean fold-rise ratio: hMPV preF = 5.3-6.1; postF = 4.6-6.5 and PIV3 preF = 13.9-14.2; postF = 11.0-12.1); a second injection did not further increase antibody levels in these seropositive children. Binding antibody responses were generally preF biased. CONCLUSIONS: mRNA-1653 was well-tolerated and boosted hMPV and PIV3 antibody levels in seropositive children aged 12 to 59 months, supporting the continued development of mRNA-1653 or its components for the prevention of hMPV and PIV3.
Sujet(s)
Virus parainfluenza humain de type 3 , Humains , Femelle , Mâle , Enfant d'âge préscolaire , Nourrisson , Virus parainfluenza humain de type 3/immunologie , Virus parainfluenza humain de type 3/génétique , Metapneumovirus/immunologie , Metapneumovirus/génétique , Méthode en simple aveugle , Infections à Paramyxoviridae/prévention et contrôle , Infections à Paramyxoviridae/immunologie , Anticorps antiviraux/sang , Vaccins contre les virus para-influenza/immunologie , Vaccins contre les virus para-influenza/administration et posologie , Vaccins contre les virus para-influenza/génétique , Immunogénicité des vaccins , ARN messagerRÉSUMÉ
We analyzed data from a community-based acute respiratory illness study involving K-12 students and their families in southcentral Wisconsin and assessed household transmission of two common seasonal respiratory viruses - human metapneumovirus (HMPV) and human coronaviruses OC43 and HKU1 (HCOV). We found secondary infection rates of 12.2% (95% CI: 8.1%-17.4%) and 19.2% (95% CI: 13.8%-25.7%) for HMPV and HCOV, respectively. We performed individual- and family-level regression models and found that HMPV transmission was positively associated age of the index case (individual model: p = .016; family model: p = .004) and HCOV transmission was positively associated with household density (family model: p = .048). We also found that the age of the non-index case was negatively associated with transmission of both HMPV (individual model: p = .049) and HCOV (individual model: p = .041), but we attributed this to selection bias from the original study design. Understanding household transmission of common respiratory viruses like HMPV and HCOV may help to broaden our understanding of the overall disease burden and establish methods to prevent the spread of disease from low- to high-risk populations.
Sujet(s)
Infections à coronavirus , Caractéristiques familiales , Metapneumovirus , Infections à Paramyxoviridae , Humains , Infections à Paramyxoviridae/transmission , Infections à Paramyxoviridae/épidémiologie , Wisconsin/épidémiologie , Femelle , Jeune adulte , Mâle , Infections à coronavirus/transmission , Infections à coronavirus/épidémiologie , Adulte , Adolescent , Enfant , Coronavirus , Saisons , Adulte d'âge moyen , Enfant d'âge préscolaire , Infections de l'appareil respiratoire/transmission , Infections de l'appareil respiratoire/épidémiologie , Infections de l'appareil respiratoire/virologieRÉSUMÉ
Respiratory viral infections remain a leading cause of morbidity and mortality. Using a murine model of human metapneumovirus, we identified recruitment of a C1q-expressing inflammatory monocyte population concomitant with viral clearance by adaptive immune cells. Genetic ablation of C1q led to reduced CD8+ T-cell function. Production of C1q by a myeloid lineage was necessary to enhance CD8+ T-cell function. Activated and dividing CD8+ T cells expressed a C1q receptor, gC1qR. Perturbation of gC1qR signaling led to altered CD8+ T-cell IFN-γ production, metabolic capacity, and cell proliferation. Autopsy specimens from fatal respiratory viral infections in children exhibited diffuse production of C1q by an interstitial population. Humans with severe coronavirus disease (COVID-19) infection also exhibited upregulation of gC1qR on activated and rapidly dividing CD8+ T cells. Collectively, these studies implicate C1q production from monocytes as a critical regulator of CD8+ T-cell function following respiratory viral infection.
Sujet(s)
Lymphocytes T CD8+ , Monocytes , Lymphocytes T CD8+/immunologie , Lymphocytes T CD8+/métabolisme , Animaux , Monocytes/immunologie , Monocytes/métabolisme , Humains , Souris , Metapneumovirus/immunologie , COVID-19/immunologie , COVID-19/virologie , COVID-19/anatomopathologie , COVID-19/métabolisme , Complément C1q/métabolisme , Complément C1q/génétique , SARS-CoV-2/immunologie , Souris de lignée C57BL , Interféron gamma/métabolisme , Activation des lymphocytes/immunologie , Infections de l'appareil respiratoire/immunologie , Infections de l'appareil respiratoire/virologie , Infections de l'appareil respiratoire/anatomopathologie , Infections de l'appareil respiratoire/métabolisme , Infections à Paramyxoviridae/immunologie , Infections à Paramyxoviridae/virologie , Infections à Paramyxoviridae/métabolismeRÉSUMÉ
PURPOSE: The objective of this study was to examine the molecular epidemiology and clinical characteristics of HMPV infection among children with ARIs in Nanjing. METHODS: The respiratory samples were collected from 2078 children (≤ 14 years) with acute respiratory infections and were tested for HMPV using real-time RT-PCR. Amplification and sequencing of the HMPV G gene were followed by phylogenetic analysis using MEGA 7.0. RESULT: The detection rate of HMPV among children was 4.7% (97/2078), with a concentration in those under 5 years of age. Notably, the peak season for HMPV prevalence was observed in winter. Among the 97 HMPV-positive samples, 51.5% (50/97) were available for characterization of the HMPV G protein gene. Phylogenetic analysis indicated that the sequenced HMPV strains were classified into three sublineages: A2c111nt - dup (84.0%), B1 (2.0%), and B2 (14.0%). CONCLUSION: There was an incidence of HMPV among hospitalized children during 2021-2022 in Nanjing with A2c111nt - dup being the dominant strain. This study demonstrated the molecular epidemiological characteristics of HMPV among children with respiratory infections in Nanjing, China.
Sujet(s)
Metapneumovirus , Épidémiologie moléculaire , Infections à Paramyxoviridae , Phylogenèse , Infections de l'appareil respiratoire , Saisons , Humains , Metapneumovirus/génétique , Metapneumovirus/classification , Metapneumovirus/isolement et purification , Chine/épidémiologie , Enfant d'âge préscolaire , Enfant , Infections à Paramyxoviridae/épidémiologie , Infections à Paramyxoviridae/virologie , Nourrisson , Mâle , Femelle , Infections de l'appareil respiratoire/épidémiologie , Infections de l'appareil respiratoire/virologie , Adolescent , Incidence , Nouveau-né , Prévalence , GénotypeRÉSUMÉ
Numerous viruses have been found to exploit glycoconjugates expressed on human cells as their initial attachment factor for viral entry and infection. The virus-cell glycointeractome, when characterized, may serve as a template for antiviral drug design. Heparan sulfate proteoglycans extensively decorate the human cell surface and were previously described as a primary receptor for human metapneumovirus (HMPV). After respiratory syncytial virus, HMPV is the second most prevalent respiratory pathogen causing respiratory tract infection in young children. To date, there is neither vaccine nor drug available to prevent or treat HMPV infection. Using a multidisciplinary approach, we report for the first time the glycointeractome of the HMPV fusion (F) protein, a viral surface glycoprotein that is essential for target-cell recognition, attachment, and entry. Our glycan microarray and surface plasmon resonance results suggest that Galß1-3/4GlcNAc moieties that may be sialylated or fucosylated are readily recognized by HMPV F. The bound motifs are highly similar to the N-linked and O-linked glycans primarily expressed on the human lung epithelium. We demonstrate that the identified glycans have the potential to compete with the cellular receptors used for HMPV entry and consequently block HMPV infection. We found that lacto-N-neotetraose demonstrated the strongest HMPV binding inhibition in a cell infection assay. Our current findings offer an encouraging and novel avenue for the design of anti-HMPV drug candidates using oligosaccharide templates.IMPORTANCEAll cells are decorated with a dense coat of sugars that makes a sugar code. Many respiratory viruses exploit this sugar code by binding to these sugars to cause infection. Human metapneumovirus is a leading cause for acute respiratory tract infections. Despite its medical importance, there is no vaccine or antiviral drug available to prevent or treat human metapneumovirus infection. This study investigates how human metapneumovirus binds to sugars in order to more efficiently infect the human host. We found that human metapneumovirus binds to a diverse range of sugars and demonstrated that these sugars can ultimately block viral infection. Understanding how viruses can take advantage of the sugar code on our cells could identify new intervention and treatment strategies to combat viral disease.
Sujet(s)
Metapneumovirus , Infections à Paramyxoviridae , Polyosides , Récepteurs viraux , Protéines de fusion virale , Attachement viral , Humains , Lignée cellulaire , Metapneumovirus/métabolisme , Metapneumovirus/physiologie , Infections à Paramyxoviridae/virologie , Infections à Paramyxoviridae/métabolisme , Polyosides/métabolisme , Liaison aux protéines , Récepteurs viraux/composition chimique , Récepteurs viraux/métabolisme , Protéines de fusion virale/métabolisme , Pénétration virale , Interactions hôte-microbes , Protéoglycanes à sulfate d'héparane/métabolismeRÉSUMÉ
BACKGROUND: Influenza, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV) are common respiratory viruses causing similar symptoms. Optimal tools to assess illness severity for these viruses have not been defined. Using the Hospitalized Acute Respiratory Tract Infection (HARTI) study data, we report symptom severity by clinician-rated clinical severity scores (CSS) in adults with influenza, RSV, or hMPV and correlations between CSS and patient-reported outcomes (PROs). METHODS: HARTI was a global epidemiologic study in adults hospitalized with acute respiratory tract infections. Patients were assessed at enrollment within 24 h of admission with CSS and twice during hospitalization with CSS, Respiratory Infection Intensity and Impact Questionnaire™ (RiiQ™), and EQ-5D-5L. Data were summarized descriptively, stratified by pathogen and baseline and hospitalization characteristics. Domain (general, upper respiratory, and lower respiratory) and sign/symptom subscores are presented for CSS; sign/symptom subscores are presented for RiiQ™ results. RESULTS: Data from 635 patients with influenza, 248 with RSV, and 107 with hMPV were included. At enrollment, total CSS and general and lower respiratory signs/symptoms (LRS) scores were higher for RSV and hMPV than influenza. Between-pathogen differences were greatest for LRS scores. Dyspnea, rales/rhonchi, wheezing, and shortness of breath scores trended higher for RSV and hMPV than influenza. RiiQ™ scores for cough, fatigue, and short of breath were strongly correlated with corresponding clinician-rated symptoms. CONCLUSIONS: These findings support the use of PROs (e.g., the RiiQ™) correlating with clinician assessments to gauge patient well-being and aid patient management by accurately assessing respiratory illness severity due to RSV, hMPV, or influenza.
Sujet(s)
Hospitalisation , Grippe humaine , Metapneumovirus , Infections à Paramyxoviridae , Infections à virus respiratoire syncytial , Infections de l'appareil respiratoire , Indice de gravité de la maladie , Humains , Metapneumovirus/isolement et purification , Mâle , Femelle , Infections de l'appareil respiratoire/virologie , Infections de l'appareil respiratoire/épidémiologie , Adulte d'âge moyen , Infections à virus respiratoire syncytial/virologie , Infections à virus respiratoire syncytial/complications , Infections à virus respiratoire syncytial/épidémiologie , Grippe humaine/virologie , Grippe humaine/complications , Grippe humaine/épidémiologie , Adulte , Infections à Paramyxoviridae/virologie , Infections à Paramyxoviridae/épidémiologie , Infections à Paramyxoviridae/complications , Sujet âgé , Jeune adulte , Virus respiratoire syncytial humain/isolement et purification , Sujet âgé de 80 ans ou plus , AdolescentRÉSUMÉ
Paramyxoviruses are a group of single-stranded, negative-sense RNA viruses, some of which are responsible for acute human disease, including parainfluenza virus, measles virus, Nipah virus and Hendra virus. In recent years, a large number of novel paramyxoviruses, particularly members of the genus Jeilongvirus, have been discovered in wild mammals, suggesting that the diversity of paramyxoviruses may be underestimated. Here we used hemi-nested reverse transcription PCR to obtain 190 paramyxovirus sequences from 969 small mammals in Hubei Province, Central China. These newly identified paramyxoviruses were classified into four clades: genera Jeilongvirus, Morbillivirus, Henipavirus and Narmovirus, with most of them belonging to the genus Jeilongvirus. Using Illumina sequencing and Sanger sequencing, we successfully recovered six near-full-length genomes with different genomic organizations, revealing the more complex genome content of paramyxoviruses. Co-divergence analysis of jeilongviruses and their known hosts indicates that host-switching occurred more frequently in the evolutionary histories of the genus Jeilongvirus. Together, our findings demonstrate the high prevalence of paramyxoviruses in small mammals, especially jeilongviruses, and highlight the diversity of paramyxoviruses and their genome content, as well as the evolution of jeilongviruses.
Sujet(s)
Infections à Paramyxoviridae , Paramyxovirinae , Paramyxovirinae/génétique , Infections à Paramyxoviridae/épidémiologie , Infections à Paramyxoviridae/médecine vétérinaire , Mammifères , Chine , Phylogenèse , Génome viral , Spécificité d'hôteRÉSUMÉ
The characteristics of severe human parainfluenza virus (HPIV)-associated pneumonia in adults have not been well evaluated. We investigated epidemiologic and clinical characteristics of 143 patients with severe HPIV-associated pneumonia during 2010-2019. HPIV was the most common cause (25.2%) of severe virus-associated hospital-acquired pneumonia and the third most common cause (15.7%) of severe virus-associated community-acquired pneumonia. Hematologic malignancy (35.0%), diabetes mellitus (23.8%), and structural lung disease (21.0%) were common underlying conditions. Co-infections occurred in 54.5% of patients admitted to an intensive care unit. The 90-day mortality rate for HPIV-associated pneumonia was comparable to that for severe influenza virus-associated pneumonia (55.2% vs. 48.4%; p = 0.22). Ribavirin treatment was not associated with lower mortality rates. Fungal co-infections were associated with 82.4% of deaths. Clinicians should consider the possibility of pathogenic co-infections in patients with HPIV-associated pneumonia. Contact precautions and environmental cleaning are crucial to prevent HPIV transmission in hospital settings.
Sujet(s)
Infections communautaires , Centres de soins tertiaires , Humains , Mâle , Femelle , Adulte d'âge moyen , Infections communautaires/épidémiologie , Infections communautaires/virologie , République de Corée/épidémiologie , Sujet âgé , Adulte , Pneumonie associée aux soins/épidémiologie , Pneumopathie virale/épidémiologie , Pneumopathie virale/mortalité , Co-infection/épidémiologie , Infections à Paramyxoviridae/épidémiologie , Infections à Paramyxoviridae/mortalité , Histoire du 21ème siècle , Infection croisée/épidémiologie , Jeune adulte , Sujet âgé de 80 ans ou plusRÉSUMÉ
The Paramyxoviridae family encompasses medically significant RNA viruses, including human respiroviruses 1 and 3 (RV1, RV3), and zoonotic pathogens like Nipah virus (NiV). RV3, previously known as parainfluenza type 3, for which no vaccines or antivirals have been approved, causes respiratory tract infections in vulnerable populations. The RV3 fusion (F) protein is inherently metastable and will likely require prefusion (preF) stabilization for vaccine effectiveness. Here we used structure-based design to stabilize regions involved in structural transformation to generate a preF protein vaccine antigen with high expression and stability, and which, by stabilizing the coiled-coil stem region, does not require a heterologous trimerization domain. The preF candidate induces strong neutralizing antibody responses in both female naïve and pre-exposed mice and provides protection in a cotton rat challenge model (female). Despite the evolutionary distance of paramyxovirus F proteins, their structural transformation and local regions of instability are conserved, which allows successful transfer of stabilizing substitutions to the distant preF proteins of RV1 and NiV. This work presents a successful vaccine antigen design for RV3 and provides a toolbox for future paramyxovirus vaccine design and pandemic preparedness.
Sujet(s)
Anticorps neutralisants , Anticorps antiviraux , Sigmodontinae , Protéines de fusion virale , Vaccins antiviraux , Animaux , Femelle , Protéines de fusion virale/immunologie , Protéines de fusion virale/génétique , Protéines de fusion virale/composition chimique , Souris , Vaccins antiviraux/immunologie , Anticorps neutralisants/immunologie , Anticorps antiviraux/immunologie , Humains , Souris de lignée BALB C , Infections à Paramyxoviridae/prévention et contrôle , Infections à Paramyxoviridae/immunologie , Infections à Paramyxoviridae/virologie , Virus parainfluenza humain de type 3/immunologie , Virus parainfluenza humain de type 3/génétiqueRÉSUMÉ
BACKGROUND: Parainfluenza virus (PIV) is a significant etiological agent of acute lower respiratory tract infections (ALRIs) in infants and young children. The present study has been conducted to investigate the prevalence of recently identified respiratory viruses. METHODS: In total, 543 oropharyngeal or nasopharyngeal swab samples collected from hospitalized patients with acute respiratory symptoms (ARS) between January and December 2021 (5,653 females and 4,950 males) were tested for respiratory viruses using RT-PCR. RESULTS: At least one respiratory virus was detected by RT-PCR in 119 out of 175 samples (68%). The most frequently detected virus was human rhinovirus (HRV) (34, 6.5%), followed by human parainfluenza viruses (HPIVs) (19, 3.6%), human bocavirus (HBoV) (8, 1.5%), human adenovirus (HAdV) (7, 1.3%), and human respiratory syncytial virus (HRSV) (4, 0.8%). HPIV-3 accounted for 3.6% (19/175) of all viral pathogens and was the second most frequently detected viral pathogen in our study. HPIV-3 infections peaked in the fall (November) of 2021. Phylogenetic analysis of the coding region of the viral protein HA revealed that all 35 (100%) of 35 HPIV-infected patients were infected with HPIV-3. CONCLUSIONS: HPIV was an important causative pathogen associated with ALRI in children hospitalized in Korea in the late fall of 2021, as the social distancing rules for COVID-19 were relaxed. These findings highlight the im-portance of HPIV as a cause of ALRI.